Tong Ren Tang Sinopharm (03613) announced interim results. Profit attributable to owners was approximately HK$198 million, a decrease of 15.6% year-on-year

According to the Zhitong Finance App, Tong Ren Tang Sinopharm (03613) announced its 2026 interim results, with revenue of about HK$602 million, a year-on-year decrease of 21%; profit attributable to company owners was approximately HK$198 million, a year-on-year decrease of 15.6%; and profit per share was HK$0.24.

According to the announcement, gross margin rose from 60.8% in the same period last year to 63.9% in the current period, up 3.1% year on year. At the same time, the decline in profit was less than the decline in revenue, indicating that the company's efforts in cost control and product structure optimization continued to bear fruit. During this period, the capital structure remained stable, operating cash flow was abundant, interest-bearing liabilities were extremely low, and financial buffering capacity was sufficient; at the same time, inventory amounts continued to decline, asset allocation was further focused on core business, and the overall asset structure was continuously optimized.